Startup Abcodia Banking on Preclinical Samples for Better Tests | GenomeWeb

By Tony Fong

NEW YORK (GenomeWeb News) – Diagnostic companies developing biomarker-based tests usually work with patient samples from subjects who already have a disease for comparison with samples taken from healthy subjects.

But leveraging a biobank that it has licensed from University College London, UK firm Abcodia is betting that samples that allow researchers to track changes in patients going back years to before the onset of disease and through the progression of disease can provide new methods of disease detection.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.